Tampa, Florida, United States – TheNewswire - December 6, 2022 - CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) has been granted approval from the European office for our patent in Europe, which will give protection for dissolvable strips and additional oral products, with coverage for Pharmaceuticals, Nicotine, and Cannabinoids on dissolvable strips and other oral products. Furthermore, CTT's newly approved European patent will give protection of our technology in up to 38 countries in Europe, including but not limited to Germany, United Kingdom, France, Ireland and Switzerland.

Ryan Khouri, CEO of CTT Pharma, stated that getting approval of our European Patents will allow our future partners the ability to develop and protect our technology in 38 countries and makes CTT a global company. I’m excited that we now have approval as I believe this will give CTT more opportunities. CTT Pharma will update shareholders as more information becomes available.

About CTT Pharma

CTT has patents granted and pending in over 50 countries giving CTT a global reach with our fast drug delivery technology. These patents protect our dissolvable strips and many other oral products. CTT’s dissolvable strips enter the bloodstream once dissolved in the mouth bypassing the lungs and digestive tract, allowing for better absorption, faster onset, as fast as an injection, and the ability to combine APIs.

CTT successfully received Health Canada approval for our dissolvable strips and sold out our initial product in weeks. CTT can utilize its technology into many APIs such as Nicotine, CBD, Caffeine, Vitamins and Pharmaceuticals to name a few.

CTT Pharma - 813-606-0060